Activation of CYP3A-mediated testosterone 6β-hydroxylation by tanshinone IIA and midazolam 1-hydroxylation by cryptotanshinone in human liver microsomes

References

• Atkins WM. (2006). Current views on the fundamental mechanisms of cytochrome P450 allosterism. Expert Opin Drug Metab Toxicol 2:573–579.
   PubMed Web of Science ®Google Scholar
• Backes WL, Kelley RW. (2003). Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. Pharmacol Ther 98:221–233.
   PubMed Web of Science ®Google Scholar
• Davydov DR, Halpert JR, Renaud JP, Hui Bon Hoa G. (2003). Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochem Biophys Res Commun 312:121–130.
   PubMed Web of Science ®Google Scholar
• Domanski TL, He YA, Khan KK, Roussel F, Wang Q, Halpert JR. (2001). Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40:10150–10160.
   PubMed Web of Science ®Google Scholar
• Egnell AC, Eriksson C, Albertson N, Houston B, Boyer S. (2003). Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 307:878–887.
   PubMed Web of Science ®Google Scholar
• Galetin A, Ito K, Hallifax D, Houston JB. (2005). CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180–190.
   PubMed Web of Science ®Google Scholar
• Harlow GR, Halpert JR. (1998). Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA 95:6636–6641.
   PubMed Web of Science ®Google Scholar
• Hazai E, Kupfer D. (2005). Interactions between CYP2C9 and CYP2C19 in reconstituted binary systems influence their catalytic activity: possible rationale for the inability of CYP2C19 to catalyze methoxychlor demethylation in human liver microsomes. Drug Metab Dispos 33:157–164.
   PubMed Web of Science ®Google Scholar
• He YA, Roussel F, Halpert JR. (2003). Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch Biochem Biophys 409:92–101.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Miller GP, Guengerich FP. (2000). Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929–5939.
   PubMed Web of Science ®Google Scholar
• Houston JB, Kenworthy KE. (2000). In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246–254.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Kolwankar D, Hummel MA, Tracy TS. (2002). Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos 30:1194–1200.
   PubMed Web of Science ®Google Scholar
• Khan KK, Halpert JR. (2000). Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes. Arch Biochem Biophys 373:335–345.
   PubMed Web of Science ®Google Scholar
• Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, Tracy TS. (1998). Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137–4147.
   PubMed Web of Science ®Google Scholar
• Mäenpää J, Hall SD, Ring BJ, Strom SC, Wrighton SA. (1998). Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137–155.
   PubMedGoogle Scholar
• Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF. (2009). Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 10:730–753.
   PubMed Web of Science ®Google Scholar
• Ngui JS, Chen Q, Shou M, Wang RW, Stearns RA, Baillie TA, Tang W. (2001). In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metab Dispos 29:877–886.
   PubMed Web of Science ®Google Scholar
• Ngui JS, Tang W, Stearns RA, Shou M, Miller RR, Zhang Y, Lin JH, Baillie TA. (2000). Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos 28:1043–1050.
   PubMed Web of Science ®Google Scholar
• Qiu F, Zhang R, Sun J, Jiye A, Hao H, Peng Y, Ai H, Wang G. (2008). Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 36:1308–1314.
   PubMed Web of Science ®Google Scholar
• Qiu F, Wang G, Zhang R, Sun J, Jiang J, Ma Y. (2010). Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br J Clin Pharmacol 69:656–662.
   PubMed Web of Science ®Google Scholar
• Schwab GE, Raucy JL, Johnson EF. (1988). Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33:493–499.
   PubMed Web of Science ®Google Scholar
• Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR. (1994). Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450–6455.
   PubMed Web of Science ®Google Scholar
• Subramanian M, Tam H, Zheng H, Tracy TS. (2010). CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos 38:1003–1009.
   PubMed Web of Science ®Google Scholar
• Szklarz GD, Halpert JR. (1998). Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab Dispos 26:1179–1184.
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Kuwabara T, Chun YJ, Guengerich FP. (1997). Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370–381.
   PubMed Web of Science ®Google Scholar
• Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. (1994). Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73:658–661.
   PubMed Web of Science ®Google Scholar
• Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. (2000). Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360–366.
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. (2004). The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091–38094.
   PubMed Web of Science ®Google Scholar
• Yu C, Ye S, Sun H, Liu Y, Gao L, Shen C, Chen S, Zeng S. (2009). PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem Biol Interact 177:58–64.
   PubMed Web of Science ®Google Scholar